GHSI (Guardion Health Sciences, Inc.) Gross Return on Sales

The gross profit margin of Guardion Health Science (GHSI) reflects the impact of strict FDA standards and physician trust, which create a business moat. This chart's dynamics are driven by the sale of the Activiva asset followed by the company's closure in 2024, as well as the stability of the ophthalmological supplement niche. The current figure stands at 43.00, allowing for a real-time assessment of the efficiency of production cost management.
Comprehensive metric breakdowns and analytics for Guardion Health Science (GHSI)

The scale of Guardion Health Science operations is reflected in the gross profit margin chart. This indicator measures the portion of revenue remaining after deducting direct production costs, allowing for an assessment of the business's fundamental efficiency. The high values of this metric are driven by patent protection for nutraceuticals and FDA certification, which create significant barriers to entry for competitors and ensure a high pricing premium.